Denali Therapeutics (DNLI) News Today

EP Wealth Advisors LLC purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 40,500 shares of the company's stock, valued at approximately $831,000. Se

Seven Eight Capital LP cut its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 71.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,541 shares of the company's stock after selling 52,046

Edgestream Partners L.P. bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 112,118 shares of the company's stock, valued at approximately $2,301,000. Edges

Denali Therapeutics (NASDAQ:DNLI) Sees Strong Trading Volume

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. Th

BNP Paribas Financial Markets lowered its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 62.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 72,105 shares of t

Susquehanna Fundamental Investments LLC purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 211,017 shares of the company's stoc

JPMorgan Chase & Co. boosted their price target on shares of Denali Therapeutics from $28.00 to $29.00 and gave the stock an "overweight" rating in a research note on Wednesday.

Denali Therapeutics (NASDAQ:DNLI) Shares Up 3.6%

Denali Therapeutics (NASDAQ:DNLI) Shares Down 3.1%

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) Director Steve E. Krognes sold 688 shares of the firm's stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $21.79, for a total value of $14,991.52. Following the completion of the transaction, the director now owns 52,620 shares of the company's stock, valued at approximately $1,146,589.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Wasatch Advisors LP lifted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 28.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 402,670 shares of the company's stock a

Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 5.8%

Denali Therapeutics (NASDAQ:DNLI) Trading Up 4.7%

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued on Wednesday, June 19th. Zacks Research analyst A. Chakraborty now forecasts that the company will earn ($2.86) p

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Th

Denali Therapeutics (NASDAQ:DNLI) Trading 4.1% Higher

Flagship Pioneering Inc. trimmed its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 11.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,319,968 shares of the company's stock after selling 300,0

Braidwell LP bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 461,769 shares of the company's stock, valued at approximately

Denali Therapeutics (NASDAQ:DNLI) Shares Down 3.7%

Seven Eight Capital LP acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 72,587 shares of the company's stock, va

Sectoral Asset Management Inc. lessened its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 94.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,881 shares of the company's stock after selling 242,060 sh

Rafferty Asset Management LLC lifted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 40.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 321,973 shares of the company's stock after acquiring an a

Campbell & CO Investment Adviser LLC lifted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 277.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 65,105 shares of the company's stock after purchasing

Crestline Management LP lessened its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 5.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,660,732 shares of the company's stock after selling

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have assig

Edmond DE Rothschild Holding S.A. grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 65.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 165,680 shares of the company's stock after

Principal Financial Group Inc. lifted its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 57.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,073,704 shares of the company's stock

Pathway Capital Management LP bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 69,450 shares of the company's stock, value

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at Wedbush lowered their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued to investors on Wednesday, May 8th. Wedbush analyst L. Chico now expects that the company will pos

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at HC Wainwright lifted their FY2027 EPS estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. HC Wainwright analyst A. Fein now forecasts that the c

Wedbush dropped their price target on Denali Therapeutics from $31.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday.

Denali Therapeutics (NASDAQ:DNLI) Trading Up 11.6% After Strong Earnings

HC Wainwright reissued a "buy" rating and issued a $95.00 target price on shares of Denali Therapeutics in a report on Wednesday.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same period in the prior year, the company posted ($0.80) earnings per share.